RECRUITING

Phenotyping Genetic Risk for Type 2 Diabetes

Talk to us

Conditions

Diabetes Mellitus, Type 2Geneticspolygenic risk for type 2 diabetes

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study tests the hypothesis that non-diabetic individuals with a high genetic risk score for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those with a low genetic risk score for type 2 diabetes.

Official Title

Phenotyping Children and Adults With Possible High or Low Genetic Risk for Type 2 Diabetes

Quick Facts

Study Start:2019-06-17
Study Completion:2026-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04024631

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:10 Years to 70 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 10-70 years
  2. * Prior participant of the UPenn Biobank or Center for Applied Genomics Biobank and agreed to be recontacted for future research.
  3. * Adults with BMI 25kg/m2 or higher, children and adolescents with BMI 85th percentile or higher
  1. * prior diagnosis of type 1, type 2, or secondary diabetes
  2. * use of medications that would impact glucose and insulin response such as steroids, metformin or other anti-diabetic medication
  3. * acute illness that may impact insulin and glucose dynamics
  4. * pregnancy
  5. * hypothalamic obesity or related genetic disorder of metabolism
  6. * recent systemic chemotherapy use
  7. * gastrointestinal impairment or surgery that may impact absorption
  8. * anemia
  9. * major organ system illness or any underlying condition requiring regular medication or treatment that could make implementation of the protocol or interpretation of the study results difficult
  10. * inability to comply with study protocol

Contacts and Locations

Study Contact

Jessica R Wilson, MD, MS
CONTACT
215 898-3389
jessica.wilson3@uphs.upenn.edu
Esther Oyerinde
CONTACT
esther.oyerinde@pennmedicine.upenn.edu

Principal Investigator

Jessica R Wilson, MD, MS
PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Lorraine Levitt Katz, MD
PRINCIPAL_INVESTIGATOR
Children's Hospital of Philadelphia

Study Locations (Sites)

Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States

Collaborators and Investigators

Sponsor: University of Pennsylvania

  • Jessica R Wilson, MD, MS, PRINCIPAL_INVESTIGATOR, University of Pennsylvania
  • Lorraine Levitt Katz, MD, PRINCIPAL_INVESTIGATOR, Children's Hospital of Philadelphia

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-06-17
Study Completion Date2026-06-30

Study Record Updates

Study Start Date2019-06-17
Study Completion Date2026-06-30

Terms related to this study

Keywords Provided by Researchers

  • polygenic risk for type 2 diabetes

Additional Relevant MeSH Terms

  • Diabetes Mellitus, Type 2
  • Genetics